Tesamorelin vs DSIP
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | DSIP |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | May cause grogginess upon waking, vivid dreams, or temporary headaches. |
| Best For |
Key Differences
Unique to Tesamorelin:
Unique to DSIP:
Detailed Analysis
DSIP and Tesamorelin are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose DSIP for Recovery & Healing, Sleep Quality. Choose Tesamorelin for Muscle Growth, Fat Loss.